All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Steven Treon from Dana-Farber Cancer Institute, Boston, US, about the long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib.
Steven Treon discusses the long-term follow-up of a multi-institutional trial investigating ibrutinib, which is highly active in patients with Waldenstrom's macroglobulinemia.
Long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox